Objective: The aim: The aim of this study was to investigate disease-free and overall survival in patients with stage IIII A NSCLC after neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant chemotherapy.
Patients and methods: Materials and methods: For the study, 3 groups of 65 people were taken. All patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy. All groups received 3 or 4 courses of neoadjuvant chemotherapy according to the scheme Docitaxel (Paclitaxel) and Cisplatin (Carboplatin), while groups II and III also received, respectively, neoadjuvant and adjuvant radiation therapy in the amount of 30 Gy to the chest and mediastinum. Survival was assessed using the Kaplan and Mayer scale.
Results: Results: 1. At a survival period of 6 months, the results of relapse-free survival in the NCRT and NCT groups do not differ. 2. From 12 months to 5 years, the highest recurrencefree survival rates are observed in the NHL group. 3. The overall five-year survival rate in the main group was 28.1±5.9%, in the NCT group - 10.4±3.8% and - 5.8±2.0% in the NCT + RT group.
Conclusion: Conclusions: The best recurrence-free survival results are observed in the NHLT group. Also, the largest number of cases of molars morphological response, correlated with the highest survival rates, also occurs in the NHL group.
Keywords: chemotherapy; Non-small cell lung cancer; chemoradiotherapy; neoadjuvant therapy; overall survival.